当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第11期
编号:13383048
中国医学创新目次质子泵抑制剂联合伊托必利治疗胃食管反流病的效果观察(4)
http://www.100md.com 2019年4月15日 《中国医学创新》 2019年第11期
     [15]白雪冰,邓碧珠,楼红玲,等.旋覆代赭汤加减联合泮托拉唑治疗胃食管反流病临床效果观察[J].廣西医学,2017,39(3):354-356.

    [16] Vega K J,Langford-Legg T,Palacio C,et al.Females without reflux symptoms or gastroesophageal reflux disease have less distal esophageal acid exposure than males without reflux symptoms or gastroesophageal reflux disease[J].Diseases of the Esophagus:Official Journal of the International Society for Diseases of the Esophagus,2013,26(3):246-249.

    [17] Langner C,Wolf E M,Plieschnegger W,et al.Multilayered epithelium at the gastroesophageal junction is a marker of gastroesophageal reflux disease:Data from a prospective Central European multicenter study(histo GERD trial)[J].Virchows Archiv:An International Journal of Pathology,2014,464(4):409-417.

    [18] VanMeer S,Bogte A,Siersema P D,et al.Long-term follow up in patients with gastroesophageal reflux disease with specific emphasis on reflux symptoms,use of anti-reflux medication and anti-reflux surgery outcome:A retrospective study[J].Scandinavian Journal of Gastroenterology,2013,48(11):1242-1248.

    [19]史长山.康复新与雷贝拉唑、伊托必利联合方案治疗胃食管反流病的临床疗效观察[J].航空航天医学杂志,2016,27(2):222-223.

    [20]梁华荣,余伟,刘飞雄,等.雷贝拉唑联合伊托必利治疗胃食管反流病疗效观察[J].中华临床医师杂志(电子版),2011,5(24):7402-7404.

    (收稿日期:2018-09-21) (本文编辑:张爽), 百拇医药(陈创杰 梁银华 郭志勇)
上一页1 2 3 4